🇺🇸 FDA
Patent

US 11529390

PCSK9 inhibitory polypolypeptides and methods of use

granted A61KA61K38/16A61K38/55

Quick answer

US patent 11529390 (PCSK9 inhibitory polypolypeptides and methods of use) held by INSTITUT DE CARDIOLOGIE DE MONTREAL expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INSTITUT DE CARDIOLOGIE DE MONTREAL
Grant date
Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/16, A61K38/55, A61K47/6937